Harpoon Therapeutics Inc (DELISTED) (HARP:DL)
23.01
0.00 (0.00%)
USD |
NASDAQ |
Mar 11, 16:00
Harpoon Therapeutics Enterprise Value: 460.74M for March 11, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| March 11, 2024 | 460.74M |
| March 08, 2024 | 460.74M |
| March 07, 2024 | 460.31M |
| March 06, 2024 | 459.89M |
| March 05, 2024 | 459.89M |
| March 04, 2024 | 459.67M |
| March 01, 2024 | 459.24M |
| February 29, 2024 | 459.24M |
| February 28, 2024 | 459.46M |
| February 27, 2024 | 459.24M |
| February 26, 2024 | 459.03M |
| February 23, 2024 | 459.03M |
| February 22, 2024 | 459.67M |
| February 21, 2024 | 452.40M |
| February 20, 2024 | 447.48M |
| February 16, 2024 | 448.12M |
| February 15, 2024 | 448.33M |
| February 14, 2024 | 448.76M |
| February 13, 2024 | 449.19M |
| February 12, 2024 | 450.90M |
| February 09, 2024 | 448.76M |
| February 08, 2024 | 446.41M |
| February 07, 2024 | 446.19M |
| February 06, 2024 | 446.62M |
| February 05, 2024 | 347.19M |
| Date | Value |
|---|---|
| February 02, 2024 | 346.85M |
| February 01, 2024 | 346.51M |
| January 31, 2024 | 346.85M |
| January 30, 2024 | 347.53M |
| January 29, 2024 | 348.03M |
| January 26, 2024 | 348.03M |
| January 25, 2024 | 348.03M |
| January 24, 2024 | 347.86M |
| January 23, 2024 | 348.03M |
| January 22, 2024 | 347.02M |
| January 19, 2024 | 349.90M |
| January 18, 2024 | 349.73M |
| January 17, 2024 | 348.71M |
| January 16, 2024 | 348.37M |
| January 12, 2024 | 348.03M |
| January 11, 2024 | 348.88M |
| January 10, 2024 | 348.88M |
| January 09, 2024 | 347.36M |
| January 08, 2024 | 347.36M |
| January 05, 2024 | 147.03M |
| January 04, 2024 | 149.74M |
| January 03, 2024 | 146.69M |
| January 02, 2024 | 154.65M |
| December 29, 2023 | 160.91M |
| December 28, 2023 | 162.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-61.84M
Minimum
Sep 29 2022
652.48M
Maximum
Jan 19 2021
145.66M
Average
140.67M
Median
May 17 2019
Enterprise Value Benchmarks
| Merck & Co Inc | 358.08B |
| Axonics Inc | 3.107B |
| Johnson & Johnson | 368.20B |
| Boston Scientific Corp | 116.87B |
| Ambrx Biopharma Inc (DELISTED) | 1.542B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.802M |
| Revenue (Quarterly) | 4.448M |
| Total Expenses (Quarterly) | 16.59M |
| EPS Diluted (Quarterly) | -0.46 |
| Profit Margin (Quarterly) | -40.51% |
| Earnings Yield | -38.07% |
| Normalized Earnings Yield | -36.51 |